CORC

在结果中检索

CORC

浏览/检索结果: 共344条，第1-10条 帮助

已选(0)清除 条数/页：   排序方式：
Opportunities and challenges of fucoidan for tumors therapy 期刊论文
CARBOHYDRATE POLYMERS, 2024, 卷号: 324, 页码: 13
作者:  Yu, Haoyu;  Zhang, Quanbin;  Farooqi, Ammad Ahmad;  Wang, Jing;  Yue, Yang
收藏  |  浏览/下载：3/0  |  提交时间：2024/04/07
Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic EGFR mutation from a phase I 期刊论文
BMC MEDICINE, 2023, 卷号: 21, 期号: 1
作者:  Yuankai Shi;  Jianying Zhou;  Yanqiu Zhao;  Bo Zhu;  Liangming Zhang
收藏  |  浏览/下载：0/0  |  提交时间：2024/05/07
An Implantable Magnetic Vascular Scaffold for Circulating Tumor Cell Removal In Vivo 期刊论文
ADVANCED MATERIALS, 2022
作者:  Yin, Zhiwei;  Shi, Rui;  Xia, Xin;  Li, Ling;  Yang, Yanxia
收藏  |  浏览/下载：23/0  |  提交时间：2022/12/23
Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial 期刊论文
BRITISH JOURNAL OF CANCER, 2022
作者:  Qin, Shukui;  Li, Jin;  Zhong, Haijun;  Jin, Chuan;  Chen, Lili
收藏  |  浏览/下载：21/0  |  提交时间：2022/12/22
A prospective, open-label, multicenter phase IV clinical trial on the safety and efficacy of lobaplatin-based chemotherapy in advanced breast cancer 期刊论文
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 卷号: 14
作者:  Yan, Min;  Yuan, Peng;  Ouyang, Quchang;  Cheng, Ying;  Han, Guohui
收藏  |  浏览/下载：27/0  |  提交时间：2022/12/23
Drug-resistant HER2-positive breast cancer: Molecular mechanisms and overcoming strategies 期刊论文
FRONTIERS IN PHARMACOLOGY, 2022, 卷号: 13
作者:  Wu, Xiaofan;  Yang, Hongjian;  Yu, Xingfei;  Qin, Jiang-Jiang
收藏  |  浏览/下载：17/0  |  提交时间：2022/12/22
Deep learning radiomics of dual-modality ultrasound images for hierarchical diagnosis of unexplained cervical lymphadenopathy 期刊论文
BMC Medicine, 2022, 卷号: 20, 期号: 1
作者:  Zhu,Yangyang;  Meng,Zheling;  Fan,Xiao;  Duan,Yin;  Jia,Yingying
收藏  |  浏览/下载：44/0  |  提交时间：2022/09/19
First-in-human, phase I study of AK109, an anti-VEGFR2 antibody, in patients (pts) with advanced or metastatic solid tumors. 期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2022, 卷号: 40
作者:  Xu, Nong;  Zheng, Yulong;  Zhong, Haijun;  Zhao, Fuyou;  Zhou, Huan
收藏  |  浏览/下载：23/0  |  提交时间：2022/12/23
A study of AK104 (an anti-PD1 and anti-CTLA4 bispecific antibody) combined with standard therapy for the first-line treatment of persistent, recurrent, or metastatic cervical cancer (R/M CC). 期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2022, 卷号: 40
作者:  Wang, Jing;  Lou, Hanmei;  Cai, Hong-Bing;  Huang, Xin;  Li, Guiling
收藏  |  浏览/下载：16/0  |  提交时间：2022/12/23
Penpulimab plus gemcitabine in combination with cisplatin or anlotinib as first-line treatment for metastatic nasopharyngeal carcinoma (M NPC): A phase II study. 期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2022, 卷号: 40
作者:  Huang, Shuang;  Chen, Xiaozhong;  Qu, Song;  Qu, Shenhong;  Han, Yaqian
收藏  |  浏览/下载：11/0  |  提交时间：2022/12/23

©版权所有 ©2017 CSpace - Powered by CSpace